secwatch.observer — SEC 8-K summary
======================================

Issuer:     Minerva Neurosciences, Inc. (NERV)
CIK:        0001598646
Form:       8-K
Filed at:   2026-04-02T23:59:59+00:00
Accession:  0001193125-26-140148
Event type: leadership
Sentiment:  neutral
Materiality: 0.45
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Minerva Neurosciences President resigns; James O'Connor named Chief Business Officer and General Counsel
--------------------------------------------------------------------------------

- Geoffrey Race resigned as President effective March 31, 2026 after 16 years with the company.
- Race will serve as consultant from April 15, 2026 to April 14, 2027 at £333/hour (min 35 hrs/month).
- James O'Connor appointed Chief Business Officer and General Counsel effective April 21, 2026.
- Press release highlights focus on roluperidone for negative symptoms of schizophrenia and planned Phase 3 trial.
- Race receives full vesting of outstanding stock options with exercise period extended to January 1, 2030.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1598646/000119312526140148/0001193125-26-140148-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1598646/000119312526140148/d143634d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-140148

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer